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Introduction
In mammals the de novo appearance and continued
increase in vascular networks accompanying progres-
sion of follicle development suggests that ovarian func-
tion is intimately dependent on follicular angiogenesis.
Follicles increase their granulosa cell number and
acquire a peripheral theca layer in which new blood ves-
sels form (vasculogenesis) during the transition from a
compact, avascular primary to a vascular secondary fol-
licle. Beyond this stage follicular growth becomes
gonadotropin dependent and results in the formation
of a centrally located, fluid-filled antrum possibly
mediated by changes in vascular permeability. Forma-
tion of antrum coincides with continued follicular
angiogenesis resulting in the development of an intri-
cate vascular mesh, which consists of two concentric
vascular networks in the peripheral theca layer (angio-
genesis) (1). These newly formed ovarian blood vessels
likely secure an increasing supply of gonadotropins,
growth factors, oxygen, steroid precursors, as well as
other substances to the growing follicle (2).
The regulation of follicular angiogenesis is poorly
understood (1–7). As suggested from expression analy-
sis (2, 5), one of the prime candidates regulating ovari-
an blood vessel formation is VEGF, also called VEGF-A
(8), acting through one of its two receptors or both (8).
Further evidence for a role of VEGF in the regulation
of gonadotropin-dependent ovarian follicular angio-
genesis and folliculogenesis is derived from functional
studies. For example, administration of substances that
inactivate VEGF block the development and function
of preovulatory follicles as demonstrated by analysis of
ovarian histology (2, 5) or hormone measurements (6).
Blockage of the function of the VEGF receptor 2
(VEGFR-2) receptor alters follicular hormone secretion,
suggesting that the intraovarian effect of VEGF might
be mediated by this receptor (7). The specific mecha-
nism by which follicular development was blocked in
these previous studies remains unclear, however. In this
study we will specifically investigate whether the
VEGF/VEGFR-2 pathway, which is involved in the reg-
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ulation of angiogenesis, survival of endothelial cells,
and vascular permeability (8), plays a critical role for
gonadotropin-dependent folliculogenesis. In addition,
interpretation of results from previous studies (2, 5–7)
is complicated by the fact that all of them were done in
animals with an active feedback mechanism. Because
administration of antiangiogenic agents can also influ-
ence hormonal feedback loops between the ovary and
pituitary gland (6, 7), some changes observed in fol-
liculogenesis might be due to this effect. To evaluate
the intraovarian role of the VEGFR-2 pathway for
gonadotropin-dependent follicle development we
chose a model, the prepuberally hypophysectomized
(HX) mouse, in which active feedback is absent. In such
a model advanced follicle growth and maturation is
normally absent; however, follicle development to the
preovulatory stage can be stimulated under controlled
conditions by the administration of exogenous
gonadotropins. Using HX mice, we demonstrate that
exogenously administered gonadotropins are unable to
drive follicle development to the preovulatory stage in
the presence of antiangiogenic agent in form of
VEGFR-2–neutralizing Ab’s. This inhibition of follicu-
lar development is caused by arrest of follicular angio-
genesis and a reduction in antrum formation. We con-
clude that the intraovarian VEGF/VEGFR-2 pathway is
critical for gonadotropin-dependent follicle angiogen-
esis and follicular development.
Methods
Experimental design. The experiments were designed to
investigate the role of VEGFR-2–mediated angiogene-
sis for gonadotropin-dependent follicle development.
We used female CD-1 mice hypophysectomized before
day 24 of life (Charles River Laboratories Inc., Wilm-
ington, Massachusetts, USA). Follicle development in
such animals arrests at the advanced preantral or early
antral stage due to the absence of gonadotropins (9),
and mature, preovulatory follicles are generally absent.
Advanced preantral follicles are highly responsive to
gonadotropins, and the development of mature, antral
follicles can be induced by exogenously administered
gonadotropins over a 3- to 4-day period (gonadotropin-
dependent growth) (9–11). Absence of pituitary glands
in such a model can be verified indirectly by demon-
strating (a) insignificant weight gain (< 1.5 g) over a 
1-week period after arrival in the laboratory (12) and (b)
vaginal smears typical for a low-estrogenic state. Only
animals that met these criteria were included in the
study and were randomly assigned to one of four
groups 1 week after arrival.
Animals in the stimulation group (n = 10 per time
point) received saline injection (250 µl) in the evening
of days 8 and 10 after arrival. In the morning of day 9
after arrival, animals received a single dose of 20 IU
pregnant mare serum gonadotropins (PMSG) (Sigma-
Aldrich, St. Louis, Missouri, USA) to induce
gonadotropin-dependent follicle development. Ani-
mals were sacrificed 24 hours (experimental day 1), 48
hours (experimental day 2), and 72 hours (experimen-
tal day 3) after PMSG injection corresponding to day
10, 11, or 12 after arrival.
Animals in the treatment group (n = 10 per time
point) received rat anti–VEGFR-2 Ab (800 µg dissolved
in 250 µl in the evening of day 8 and 10) (DC 101;
ImClone Systems, New York, New York, USA) (13) after
arrival. PMSG was administered as described for the
stimulation group. Animals were sacrificed at the same
time points as in the stimulation group.
Animals in the control group (n = 10 per time point)
were injected with saline in the evening of day 8 and day
10 (250 µl of saline), simulating Ab injection in the
treatment group, and in the morning of day 9 (200 µl
of saline), simulating the PMSG injection. Animals
were sacrificed at the same time points as in the stimu-
lation group. Inclusion of this group allowed defini-
tion of the type and number of follicles developing dur-
ing the time of experimental intervention in the
absence of gonadotropins and antiangiogenic agent.
Animals in the baseline group (n = 10) received no inter-
vention and were sacrificed in the evening of day 8 after
arrival. This allowed definition of the type and number
of follicles present before any intervention was initiated.
One hour before sacrifice all animals were injected
intraperitoneally with 1 ml BrdU reagent (00-0103;
Zymed Laboratories Inc., South San Francisco, Cali-
fornia, USA) per 100 g mouse.
Dosage of anti–VEGFR-2 and effect of nonspecific rat IgG. A
dose-response curve using anti–VEGFR-2 (DC101) had
been performed injecting three groups (three animals
per group) at the following dosages twice, 48 hours
apart: 0.4 mg, 0.8 mg, and 1.6 mg. The effect of DC101
on PMSG-dependent folliculogenesis was evaluated 3
days after injections were initiated. The same level of
inhibitory response was achieved with injection of 0.8
mg or 1.6 mg of Ab. Because there was no difference in
the level of inhibition between these two dosages, the
0.8-mg dose per animal was chosen. In our experiments
we used saline instead of nonspecific rat IgG (Sigma-
Aldrich) for sham injections because nonspecific rat
IgG increased background staining in immunohisto-
chemistry. Because it is possible that rat IgG could have
nonspecific effects on gonadotropin-dependent folli-
cle development, we tested for this possibility by evalu-
ating follicle development induced with PMSG in the
presence and absence of nonspecific rat IgG Ab (two
dosages of 800 µg 2 days apart; three animals per
group), and no effect of Ab on follicle development was
detected. Therefore, we concluded that sham injections
of saline can replace control Ab injections.
Histology. Following sacrifice, both ovaries and uterus
were removed. One ovary and the uterus were fixed in
formalin. The second ovary, called the contralateral
ovary, was embedded in OCT, flash-frozen in isopen-
tane cooled by dry ice, and stored at –80°C. The for-
malin-fixed organs were weighed after drying with
fluid-absorbing paper tissue. Serial 10-µm ovarian tis-
sue sections were cut through all formalin-fixed
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ovaries, and each section was stained with H&E. Eval-
uation of serial sections representing whole ovaries
allows quantification of the gonadotropin-dependent
dynamics of follicle development over time under the
different experimental conditions by counting the total
number of follicles present in individual ovaries.
Evaluation of individual follicles. To evaluate the effects
of experimental interventions at the level of individual
follicles, such follicles of interest located in the con-
tralateral ovary from each animal were characterized by
(a) examining the development of a microvascular net-
work by staining against PECAM (platelet endothelial
cell adhesion molecule) (b) quantifying the number of
mitotic granulosa cells staining for BrdU, and (c) deter-
mining the presence of proliferating endothelial cells
through colocalization of BrdU and PECAM.
Selection of follicles eligible for evaluation. To identify fol-
licles suitable for immunohistochemical or immuno-
fluorescent evaluation fifty 10-µm sections from the
center of each frozen, contralateral ovary were obtained,
every fifth section was stained with H&E, and those sec-
tions were inspected. Sections that went through the
center of the follicle (largest cross section) were catego-
rized by using a modified follicle classification devel-
oped by Pedersen and Peters (14). This classification
describes three distinct types of follicles, whose devel-
opment is gonadotropin dependent (Figure 1c): class 5b
follicles with more than three layers of granulosa cells,
with or without a very few fluid pockets and the oocyte
visible; class 6 follicles, which have multiple fluid pock-
ets with the oocyte visible; preovulatory follicles (class
7), which have a single continuous cavity containing fol-
licular fluid surrounded by multiple layers of granulosa
cells with the oocyte sometimes located in a well-formed
cumulus stalk (class 8). A maximum of three follicles,
each belonging to one of the three classes, per con-
tralateral ovary could be selected for further characteri-
zation by immunohistochemical or immunofluores-
cent means. Such follicles of interest also had to meet a
second condition to become eligible for evaluation: they
had to be nonatretic. Atretic follicles can be differenti-
ated from nonatretic follicles by the number of apop-
totic granulosa cells. Atretic follicles are characterized
by a high number of apoptotic granulosa cells (>10%),
and their fate is mostly elimination by atresia (15).
Nonatretic follicles (<10% apoptotic cells) have the
potential to develop into preovulatory follicles. H&E
staining allows identification of such nonatretic or
“healthy” follicles. These follicles contain a normal-
shaped oocyte surrounded by granulosa cells that were
regularly apposed on an intact basement membrane
with a normal appearance of granulosa cell nuclei with-
out signs of pyknosis (5). To confirm the correct histo-
logical assessment an adjacent section of the same folli-
cle was stained for apoptosis by immunohistochemical
means (see below). An H&E-stained cross section
through a follicle meeting all the inclusion criteria is
called the index section and is given the number 0. 
Figure 1
(a) H&E staining of mouse ovaries on experimental day 3. Top panel, low-power photomicrographs of three representative whole ovaries from
HX animals not treated with hormone (C, control); no advanced antral stage follicles present. Middle panel, low-power photomicrographs
of three representative whole ovaries from HX animals stimulated with PMSG (S, stimulation); at least three advanced antral stage follicles
present in each section. Lower panel, low-power photomicrographs of three representative whole ovaries from HX animals treated with PMSG
plus anti–VEGFR-2 Ab (T, treatment); early antral stage follicles present in each section. (b) Intermediate-power photomicrographs of a con-
trol, stimulation, and treatment ovary (boxed area in a). Numbers indicate classes of follicular development. (c) Follicle classification.
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Sections immediately preceding and following the index
section are identified by a number preceded by a minus
(–) or plus (+) sign.
Immunohistochemistry. Vascular endowment of a fol-
licle of interest was evaluated in the tissue sections
immediately following the index section by staining
against PECAM (16) using immunohistochemistry
(section +1) or immunofluorescence (section +2),
according to the manufacturer’s instructions
(PharMingen, San Diego, California, USA). To detect
signals immunohistochemically, peroxidase staining
was performed with diaminobenzidine tetrahy-
drochloride (DAB) as a chromogen (brown color)
(DAB substrate kit; Vector Laboratories, Burlington,
California, USA). Counterstaining to detect nuclei
was performed with hematoxylin. Detection by
immunofluorescent means was performed by using a
fluorescent conjugate of streptavidin (Alexa Fluor
488; Molecular Probes Inc., Eugene, Oregon, USA),
which emits green light. Nuclear staining was per-
formed with DAPI (Vector Laboratories).
Granulosa cell proliferation (section +3) was identi-
fied with a biotinylated mouse anti-BrdU primary Ab
(BrdU Zymed kit; Zymed Laboratories Inc., South San
Francisco, California, USA) following the manufactur-
er’s instruction. After incubating with streptavidin-per-
oxidase for 10 minutes at 25°C, DAB (brown color) was
used as a chromogen for single labeling (Vector Labo-
ratories). Section +4 was stained with hematoxylin,
which allowed counting the total number of granulosa
cells using a computer program (see below). For dual
labeling to identify proliferating endothelial cells, slides
were first incubated with anti-PECAM Ab as described
above and visualized with either DAB (brown color) for
immunohistochemistry (section –1) or with Alexa Fluo
488 (green color) for immunofluorescence (Molecular
Probes Inc.) (section –2). This was followed by incuba-
tion of the same sections with Ab against BrdU as
described above and developed with either the chro-
mogen VIP (purple color) for immunohistochemistry
(Vector Laboratories (section –1) or with Alexa Fluor
594 (red color) (Molecular Probes Inc.) for immuno-
fluorescence (section –2). Proliferating endothelial cells
were identified as purple areas surrounded by a brown
area in immunohistochemistry or as yellow areas
through superposition of green and red color. For qual-
ity assurance, a Wilms tumor (provided by Jessica Kan-
del, Columbia University, New York, New York, USA)
was included, because proliferating endothelial cells are
frequent in tumors (data not shown).
Apoptotic cells (section –3) were detected by TUNEL,
using an in situ detection kit (ApopTag; Intergen Co.,
Purchase, New York, New York, USA), according to the
manufacturer’s instruction. Testing for apoptosis was
used to verify that individual follicles selected for
immunohistochemical evaluation were nonatretic. In
addition, the ratio of atretic versus nonatretic follicles
was evaluated in a randomly selected section from the
contralateral ovaries for the different experimental con-
ditions. For quality assurance a Wilms tumor treated
with antiangiogenic agent (provided by Jessica Kandel)
was included, because apoptotic cells are frequent in
such treated tumors (data not shown).
Type and number of follicles, whose growth is gonadotropin
dependent. Gonadotropin-dependent follicle growth
starts at the advanced preantral or early antral stage
and culminates in the development of mature antral
follicles ready to ovulate (9). The modified classifica-
tion of follicle development by Pedersen and Peters (14)
(Figure 1c) was used to count the total number of class
5b, class 6, and preovulatory follicles contained in one
whole ovary from each animal. Such a numerical
approach allowed us to compare the dynamics of
gonadotropin-dependent follicle development between
the different experimental groups over time. To avoid
double counting, only follicles in which the nucleus of
the oocyte was clearly visible were counted. Quantifi-
cation was performed by two investigators in a blinded
fashion, and the coefficient of correlation for follicle
counts between the two investigators was 0.88.
Quantification by immunohistochemistry. Quantitative
analysis of PECAM, BrdU (proliferation), and 3′-end
TUNEL labeling (apoptosis) was performed using an
image analysis system linked to a Nikon Eclipse E800
camera, and the data were processed using ImagePro
Plus Version 4.01 (Media Cybernetics, Silver Spring,
Maryland, USA). Follicles of interest were identified,
and the theca and granulosa cell compartments were
outlined and analyzed separately.
Vasculature identified by PECAM labeling. Quantifica-
tion of vasculature (section +1) present in individual
follicles belonging to class 5b, class 6, or the preovu-
latory stage from the contralateral ovary of each ani-
mal was performed whenever possible. The total area
of the theca cell compartment was outlined per
largest cross section of each follicle of interest and was
measured at ×300 (class 5b and class 6) or at ×200
(preovulatory follicle) magnification, and the area was
expressed as micrometers squared. Subsequently, the
total endothelial cell area, that is, PECAM-positive
cells located within this compartment, were identified
(total amount of vasculature), and the area was
expressed as micrometers squared. Vascular density
expressed as percentage was calculated by forming a
ratio of PCEAM-positive area divided by the total
theca layer area multiplied by 100.
Proliferating cells identified by BrdU labeling. Cross sections
through follicles of class 5b or 6 were analyzed at a mag-
nification of ×300 and preovulatory follicles at ×200.
Granulosa cells. Granulosa cell proliferation (section +3)
was quantified in the same follicles whose vasculature
had been analyzed. The image analysis system was set
up to measure the number of dark-stained nuclei (BrdU
positive) using the segmentation part of the computer
program. The adjacent section, which was stained with
hematoxylin, allowed for counting of the total number
of granulosa cells identified as blue-stained nuclei in the
follicle of interest. A granulosa cell proliferation index
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was formed (i.e., BrdU-positive cells expressed as a per-
centage of the total number of granulosa cells from the
cross section of the follicle of interest). Because the
number of granulosa cells per largest cross section cor-
relates closely with the total number of granulosa cells
for the same follicle, this number is representative of the
total number of granulosa cells per follicle (17).
Proliferating endothelial cells. Proliferating endothelial
cells (section –1) were identified manually by colocal-
ization of BrdU and PECAM, because the automated
image analysis program failed to identify double-labeled
cells reliably. Because the number of dividing endothe-
lial cells in developing follicles was generally low, a qual-
itative approach was used, and the follicles of interest
were classified into two categories based on the presence
(+) or absence (–) of dividing endothelial cells.
Atresia. Atresia, a default pathway to eliminate folli-
cles, is most prominent in class 5b follicles (9). To
quantify the extent of atresia, an index was formed by
counting the number of atretic follicles belonging to
class 5b and beyond divided by the total number of
advanced secondary or tertiary (antral) follicles in ran-
domly selected cross sections from each contralateral
ovary. One cross section per ovary was analyzed, and
therefore a total of ten cross sections from ten ovaries
in the baseline, control, stimulation, and treatment
group were evaluated.
Quantification of fluid-filled areas or antrum. The total
area of the granulosa cell compartment plus fluid-filled
spaces or antrum was outlined per largest cross section
from each follicle (section 0) selected for evaluation.
Fluid-filled areas were measured at ×300 (class 5b and
class 6) or at ×200 (preovulatory follicle) magnification,
and the areas were expressed as micrometers squared.
Serum estradiol and progesterone. Blood samples were
obtained by cardiopuncture and allowed to clot for 1
hour. The blood samples were then centrifuged (1,000 g)
for 15 minutes at room temperature, and the serum
was stored at –20°C. Estradiol and progesterone were
measured with a ligand-labeled, competitive, chemilu-
minescent immunoassay (Diagnostic Products Corp.,
Los Angeles, California, USA). The interassay coeffi-
cients of variation were 11.9% and 11.1% for estradiol
and progesterone, respectively.
Statistical analysis. Data are expressed as mean plus or
minus the standard error. ANOVA (Kruskal-Wallis) and
post hoc Dunn’s multiple comparison were used for
statistical analysis, with P values less than 0.05 consid-
ered significant (11). For nonparametric testing, the 
χ-square test was used.
Results
PMSG administration to HX mice stimulates follicular devel-
opment and angiogenesis. We counted the total number of
class 5b, class 6, and preovulatory follicles present in
whole ovaries from animals belonging to baseline
(untreated), control (saline), or stimulation (PMSG plus
saline) group to characterize the dynamics of follicle
development over time. Follicles of the class 5b type
dominated in ovaries from the baseline and the control
group (experimental days 1, 2, and 3), whereas follicles
of advanced development (those with a significant
amount of antrum) were rarely seen (Figure 1a, top
panel; Table 1). Little variation in the number of such
Table 1
Effect of PMSG or PMSG plus anti–VEGFR-2 Ab on follicular num-
ber per ovary diameter
Experimental groups Class 5b Class 6 Class 7/8
Baseline 9 ± 1.1 none none
24 hours after PMSG injection
Control 10.3 ± 1.2 noneA none
Stimulation 11.5 ± 1.4 8.5 ± 1.1B none
Treatment 8.9 ± 1.5 3.3 ± 0.9D none
48 hours after PMSG injection
Control 9.5 ± 1.3 noneA noneA
Stimulation 10.8 ± 1.5 11.5 ± 1.6 4.1 ± 0.3C
Treatment 11.1 ± 1.4 10.2 ± 1.6D none
72 hours after PMSG injection
Control 10.8 ± 1.2 noneA noneA
Stimulation 11.5 ± 1.9 12.5 ± 2.1 9.5 ± 2.1C
Treatment 10.1 ± 1.5 8.9 ± 1.1D 0.8 ± 0.1
Values are mean ± SE. Control versus stimulation: AP < 0.01; stimulation ver-
sus treatment: BP < 0.05, CP < 0.01; control versus treatment: DP < 0.01.
Table 2
Effect of PMSG or PMSG plus anti–VEGFR-2 Ab on follicular vasculature (µm2) and blood vessel density (µm2/theca layer area)
Vasculature (µm2) Blood vessel density (%)
Experimental groups Class 5b Class 6 Class 7/8 Class 5b/6 Class 6 Class 7/8
24 hours after PMSG injection
Control 1,824 ± 383B none none 13.9 ± 2.9A none none
Stimulation 2,585 ± 423D 2,944 ± 234D none 20.5 ± 2.1C 23.4 ± 1.2 none
Treatment 1,598 ± 210 1,874 ± 179 none 11.5 ± 1.1 8.5 ± 2.1 none
48 hours after PMSG injection
Control 1,681 ± 245A none none 12.5 ± 3.1A none none
Stimulation 2,199 ± 344C 3,211 ± 297D 4,355 ± 875 19.1 ± 3.8C 17.2 ± 2.1D 18.8 ± 6.0
Treatment 1,778 ± 485 1,590 ± 165 none 13.1 ± 2.1 9.5 ± 1.7 none
72 hours after PMSG injection
Control 1,581 ± 291A none none 13.1 ± 2.4A none none
Stimulation 2,345 ± 301C 3,467 ± 391D 5,347 ± 442 21.1 ± 4.7C 18.8 ± 3.4C 16.9 ± 3.8
Treatment 1,721 ± 281 1,677 ± 245 none 14.5 ± 1.9 10.1 ± 2.1 none
Values are mean ± SE. Control versus stimulation: AP < 0.05, BP < 0.01; stimulation versus treatment: CP < 0.05, DP < 0.01.
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follicles per ovary was observed between the baseline
group and the control groups (Table 1). Preovulatory
follicles (large, continuous fluid-filled cavity) dominat-
ed in stimulation group ovaries after a 72-hour expo-
sure to gonadotropins (9.5 ± 2.1 follicles per ovary) (Fig-
ure 1a, middle panel; Table 1), and few corpora lutea
were seen as well (2.5 ± 0.2 follicles per ovary). Preovula-
tory follicles were absent 24 hours after PMSG admin-
istration and started to appear 48 hours after PMSG
administration (4.1 ± 0.3 follicles per ovary). The total
number of class 5b follicles 24 hours, 48 hours, and 72
hours after PMSG administration in the stimulation
group was similar to the number seen in the control
group (Table 1). Class 6 follicles (larger areas of follicu-
lar fluid but no continuous fluid-filled cavity) were first
seen 24 hours after PMSG administration (8.5 ± 1.1 fol-
licles per ovary). The number of this type of follicle con-
tinued to increase 48 hours after PMSG administration
(11.5 ± 1.6 follicles per ovary), but no further rise was
seen 72 hours after PMSG administration (12.5 ± 2.1
follicles per ovary).
Subsequently, an analysis of the vasculature in indi-
vidual follicles belonging to class 5b, class 6, or the pre-
ovulatory stage was performed in the contralateral
ovaries of all animals in baseline, control, or stimulation
groups. There was no significant difference in the total
amount of vasculature and blood vessel density between
class 5b follicles belonging either to the baseline or the
different control groups (experimental day 1, 2, or 3)
(Table 2). Endothelial cell proliferation was generally
absent in such class 5b follicles. In the stimulation
group, the total amount of theca layer vasculature was
highest in preovulatory follicles. Class 6 follicles had less
vasculature than preovulatory follicles, but more than
class 5b follicles (Table 2). Therefore, with advancement
of follicle development, the total amount of vasculature
continued to increase (Table 1; Figure 2 and Figure 3).
Blood vessel density was similar between different types
of stimulation group follicles (class 5b to preovulatory)
for all the time points studied and ranged from 17% to
23%. It is of note that the total amount of vasculature
and blood vessel density in class 5b stimulation group
follicles was always higher when compared with follicles
of the same type found in baseline or control group
ovaries (< 15%) (Figure 2 and Table 2). This increase in
vascular density of stimulation group 5b follicles over
control (Figure 2) indicates that one of the initial steps
of gonadotropin-dependent follicular development is
an increase in follicular vasculature, which in turn
increases follicular blood supply and secures further fol-
licular growth. In general, the increase in the amount of
follicular vasculature and vascular density in stimula-
tion group follicles is due to endothelial cell prolifera-
tion because dividing endothelial cells are consistently
observed in the theca layer of follicles whose growth is
gonadotropin dependent (Figure 2 and 3; P < 0.01).
Our data demonstrate that the immature, HX mouse
model is well suited to evaluate the importance of
intraovarian follicular angiogenesis for gonadotropin-
dependent follicular development. Ovaries from ani-
mals HX before 24 days of age contain mostly imma-
ture follicles, with the most advanced cohort belonging
to class 5b. Maturation of follicles beyond this stage
accompanied by active follicular angiogenesis is
induced by the administration of exogenous gonado-
tropins (11). Hypophysectomy excludes the possibility
that alterations in hypothalamus/pituitary gland hor-
mone secretion due to changes in feedback or due to a
direct effect of anti–VEGFR-2 Ab on this unit will affect
ovarian function.
VEGFR-2 activity is required for gonadotropin-induced fol-
licular development and angiogenesis. We next examined
the effect of VEGFR-2–neutralizing Ab, an antiangio-
genic agent (13), on the dynamics of gonadotropin-
dependent follicle development and follicular angio-
genesis in animals stimulated with PMSG. Class 6
follicles (multiple fluid pockets) dominated in treat-
ment group ovaries 48 hours (10.2 ± 1.6 follicles per
ovary) and 72 hours (8.9 ± 1.1 follicles per ovary; Fig-
ure 1a, lower panel) after PMSG. Some class 6 follicles
were already seen 24 hours after PMSG stimulation
(3.3 ± 0.9 follicles per ovary) (Figure 1). Preovulatory
follicles were mostly absent at all time points exam-
ined in treatment group ovaries (Figure 1; Table 1).
Because the number of class 6 follicles is approxi-
mately the same 48 hours and 72 hours after PMSG
administration, and preovulatory follicles were rarely
Figure 2
(a–c) Immunofluorescent staining of follicular vasculature of class
5b follicles on experimental day 1. (a) C, control group follicle; (b)
S, PMSG-stimulated follicle; (c) T, treatment group follicle. Insert in
b shows proliferating endothelial cells (arrow). Green: PECAM stain-
ing for blood vessels; red: BrdU staining for cell proliferation; yellow:
combined staining indication of blood vessel proliferation.
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seen, one can conclude that administration of
anti–VEGFR-2 Ab caused an arrest of gonadotropin-
dependent follicle growth at the class 6 stage. The total
number of class 5b follicles per ovary counted on
experimental day 1, 2, and 3 after combined PMSG
and anti–VEGFR-2 Ab administration in the treat-
ment group were similar to the numbers seen in the
stimulation, control, and baseline group (Table 1).
Subsequently, an analysis of the vasculature in indi-
vidual follicles belonging to class 5b or class 6 was per-
formed in the contralateral ovaries of all treatment
group animals. The total amount of vasculature of
class 6 follicles was similar to the amount seen in class
5b follicles for all time points examined (Table 1). Thus,
advancement of follicle development to class 6 from
class 5b occurred without an increase in the total
amount of theca layer vasculature. It is of note that vas-
cular density in class 6 decreased slightly when com-
pared with the density of class 5b follicles (Table 2).
This observation may be explained by the fact that the
total area of the theca layer tissue increased due to
theca cell proliferation stimulated by PMSG in treat-
ment group follicles (unpublished observation). In con-
trast the amount of theca layer vasculature did not
change, because anti–VEGFR-2 Ab inhibited endothe-
lial cell proliferation. Therefore, the ratio of theca cells
to endothelial cells changed, which in turn caused this
decrease in vascular density.
Blocking VEGFR-2 activity interferes with antrum forma-
tion. Mature, preovulatory follicles are characterized by
the development of a large, single, central fluid-filled
antrum. To assess how anti–VEGFR-2 Ab treatment
affects gonadotropin-dependent cavity formation
activity, we compared the area of cavity of the most
advanced follicles between control, stimulation, and
treatment groups after a 72-hour exposure to a sham
injection or PMSG. The area of cavity was highest in
the most-developed follicles of the stimulation group
(Figure 1b, middle ovary) (49,920 ± 5,678 µm2), where-
as it was very low in the most-developed follicles from
the control group (upper ovary) (2,074 ± 924 µm2; 
P < 0.01). This difference is explained by the fact that
multiple preovulatory follicles with large, continuous
fluid-filled cavities were seen in PMSG-treated animals,
whereas no such follicles were detected in control
group ovaries. Some cavity formation activity occurred
in the most developed follicles from the treatment
group as demonstrated by many fluid-filled pockets
among granulosa cells in class 6 follicles (Figure 1). The
area of fluid-filled pockets measured 11,707 ± 1,144
µm2, which is significantly lower when compared with
the most-developed follicles in the stimulation group
(P < 0.01), but higher when compared with class 5b
control group follicles (P < 0.01). This observation indi-
cates some cavity formation in treatment group
ovaries, but an inability to form large, single, confluent
cavities as seen in preovulatory follicles from stimula-
tion group ovaries.
VEGFR-2 activity is required for gonadotropin-dependent
increase in granulosa cell proliferation. Significant granulosa
cell proliferation was detected in all nonatretic class 5b
follicles in baseline and control group ovaries. The pro-
liferation index of individual class 5b control group fol-
licles selected for immunohistochemical evaluation was
between 21% and 27% (dividing cells per total cell num-
ber multiplied by 100) (Figure 4; Table 3) and did not
change over time (experimental day 1, 2, and 3). In com-
parison with control follicles, the proliferation index
more than doubled in class 5b and class 6 follicles in the
stimulation group when analyzed 24 hours, 48 hours,
and 72 hours after initiation of PMSG stimulation fluc-
tuating between 40% and 50% (Figure 3; Table 3). It
declined somewhat in preovulatory follicles (Table 3). In
contrast, in the treatment group proliferative activity of
granulosa cells from class 5b or class 6 follicles was
around 30% and did not change significantly over time.
Therefore, proliferative activity in treatment group fol-
Table 3
Effect of PMSG or PMSG plus anti–VEGFR-2 Ab on granulosa cell
proliferation
Experimental groups Class 5b/6 Class 6 Class 7/8
24 hours after PMSG injection
Control 0.23 ± 0.03A none none
Stimulation 0.45 ± 0.05 0.51 ± 0.06B none
Treatment 0.37 ± 0.03C 0.31 ± 0.04 none
48 hours after PMSG injection
Control 0.27 ± 0.03A none none
Stimulation 0.49 ± 0.04B 0.52 ± 0.06B 0.39 ± 0.05
Treatment 0.32 ± 0.04 0.29 ± 0.03 none
72 hours after PMSG injection
Control 0.21 ± 0.03A none none
Stimulation 0.53 ± 0.05B 0.54 ± 0.06B 0.41 ± 0.04
Treatment 0.30 ± 0.02C 0.33 ± 0.04 none
Values are mean ± SE. Control versus stimulation: AP < 0.01; stimulation ver-
sus treatment: BP < 0.05, ; control versus treatment: CP < 0.05.
Figure 3
Immunohistochemical staining of follicular vasculature of a preovu-
latory follicle from the stimulation group ovary on experimental day 3.
Counterstaining with hematoxylin. Insert shows proliferating
endothelial cells (arrows). Brown: PECAM staining for blood vessels;
purple: BrdU staining for cell proliferation; brown surrounding pur-
ple: combined staining indication of blood vessel proliferation.
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licles was higher when compared with control group
follicles, but less when compared with stimulation
group follicles. The difference in proliferative indices
measured for the same follicle stage at each experimen-
tal day between the three groups was statistically sig-
nificant most of the time (P < 0.05; Table 3).
Blocking VEGFR-2 activity interferes with gonadotropin-
mediated prevention of atresia. Slightly more than half of all
class 5b follicles were atretic in baseline (data not shown)
and control group ovaries (experimental day 3), as
demonstrated by the presence of many follicles in which
more than 10% of granulosa cells are apoptotic (Figure
5; Table 4). In contrast, the ovaries of stimulation group
animals evaluated 72 hours after the PMSG injection
rarely displayed atretic follicles (Figure 5; Table 4). Thus,
treatment with gonadotropins is able to reverse the fate
of preexisting atretic follicles. Gonadotropins in the
presence of anti–VEGFR-2 Ab (treatment group)
reduced the number of atretic follicles to about 34%
(number of atretic follicles per total number of follicles
belonging to class 5b or higher multiplied by 100) when
compared with baseline and control ovaries. The differ-
ences between the three experimental groups were sta-
tistically significant (P < 0.05; Table 4)
Treatment with anti–VEGFR-2 Ab interferes with
gonadotropin-induced estradiol/progesterone secretion and
ovarian/uterine growth. As seen in Table 4, gonado-
tropins induced a threefold increase in serum estradi-
ol and progesterone concentrations in stimulation
group animals compared with control (P < 0.05) when
measured 72 hours after the PMSG injection. A slight
but nonsignificant rise in estradiol and progesterone
secretion was observed in the anti–VEGFR-2 treat-
ment group when compared with control. Induction
of preovulatory follicular development with PMSG
was associated with a 50% increase in ovarian weight
when compared with animals not hormonally treated
(control group: 6.0 ± 0.6 mg; PMSG-treated group:
10.1 ± 1.1 mg; P < 0.05). Treatment with anti–mouse
VEFGR-2 Ab in the presence of PMSG (anti–VEGFR-2
group) resulted in a complete suppression of the
ovarian weight gain seen for the PMSG-stimulated
group (treatment: 6.2 ± 0.5 mg; P < 0.05). PMSG
administration also induced a nearly threefold
increase in the uterine weight in the stimulation
group compared with control evaluated 72 hours
after PMSG or sham injection (control: 15.7 ± 4.2 mg;
PMSG-stimulated group: 50.3 ± 7.5 mg; P < 0.01). In
the anti–VEGFR-2 treatment group, uterine weight
failed to increase to levels seen in PMSG-stimulated
animals (28.9 ± 3.5 mg; P < 0.05).
Discussion
Administration of an anti–VEGFR-2 Ab (DC101) inhibits
gonadotropin-dependent follicular angiogenesis, which
in turn blocks development of mature antral follicles. We
conclude that the intraovarian VEGF/VEGFR-2 pathway
plays a critical mediatory role in the process of
gonadotropin-mediated follicular development.
Gonadotropins drive follicular development, and a
component of this function is derived from the effects
of gonadotropins on the vasculature of the ovary.
Administration of exogenous gonadotropins in the
form of PMSG triples the amount of follicular vascula-
ture during follicular development from immature class
5b to the mature preovulatory stage. Increase in follicu-
lar vasculature is due to active follicular angiogenesis,
which is frequently detected in growing follicles in the
form of dividing endothelial cells. Administration of 
a blocking Ab against VEGFR-2 partially inhibits
Table 4
Effect of PMSG or PMSG plus anti–VEGFR-2 Ab on atresia, steroids,
and ovarian and uterine weight 72 hours after PMSG injection
Control Stimulation Treatment
Atresia index 0.54 ± 0.04B 0D 0.34 ± 0.07E
Estradiol (pg/ml) 34 ± 3.5B 90.4 ± 11.1D 48 ± 5.6
Progesterone (ng/ml) 0.3 ± 0.09A 1.1 ± 0.37C 0.3 ± 0.08
Ovarian weight (mg) 6 ± 0.65A 10.1 ± 1.1C 6.2 ± 0.54
Uterine weight (mg) 15.7 ± 4.2B 50.3 ± 7.4C 28.9 ± 3.5
Values are mean ± SE. Control versus stimulation: AP < 0.05, BP < 0.01; stimu-
lation versus treatment: CP < 0.05, DP < 0.01; control versus treatment: EP < 0.05. 
Figure 4
Granulosa cell proliferation on experimental day 1. (a) Low-power
magnification of an ovarian cross section; (b) intermediate-power
magnification of class 5b or early class 6 follicles from each experi-
mental group. C, control group follicle; S, PMSG-stimulated follicle;
T, treatment group follicle. Proliferation is seen as black dots. Coun-
terstaining is with methyl-green.
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gonadotropin-dependent follicular development; that
is, class 5b follicles can advance to class 6 but not to the
preovulatory stage. It is of note that the total amount of
vasculature seen in class 6 follicles is similar to that seen
in class 5b in the treatment group. This observation
suggests that the Ab, while not affecting survival of pre-
existing vasculature, prevented significant endothelial
cell proliferation. Indeed, dividing endothelial cells were
rarely seen in such follicles. Thus, in the treatment
group gonadotropin-driven follicular development can
partially progress without concomitant increase in fol-
licular vasculature. This partial progression may be a
result of sufficient delivery of PMSG and other sub-
stances by preexisting vasculature to allow such partial
follicular development. On the other hand a substantial
increase in follicular vasculature may be required to
secure delivery of PMSG and other substances at levels
sufficient to permit progression to the preovulatory
stage. Based on our findings, we hypothesize that the
failure to increase follicular blood supply by increasing
the follicular amount of vasculature by angiogenesis
prohibits an increase in the delivery of substances essen-
tial for follicle development to the preovulatory stage.
Due to the specificity of the Ab (i.e., it exclusively
blocks function of VEGFR-2), one can define the
intraovarian role of the VEGF/VEGFR-2 pathway for
gonadotropin-dependent folliculogenesis. Based on
our findings, the gonadotropin-dependent induction
of angiogenesis in follicles very likely occurs by indi-
rect means. VEGF is produced by granulosa and theca
cells (1, 2, 18, 19), and it has been reported that VEGF
expression is stimulated by gonadotropins (20).
VEGFR-2 is consistently expressed on endothelial cells
found in the theca layer of follicles (19) (unpublished
observation). Thus, gonadotropins likely increase
VEGF production and secretion in follicular epithelial
cells, which in a paracrine manner acts on VEGFR-2
located on theca layer endothelial cells to induce
angiogenesis. While the VEGF/VEGFR-2 pathway
seems to be critical for endothelial cell proliferation, it
seems to be of lesser importance to secure survival of
preexisting follicular vasculature. This finding is con-
gruent with fact that follicular blood vessel are mature
vessels, i.e., endothelial cells are surrounded by peri-
cytes (unpublished observation), which are less
dependent on the VEGF/VEGFR-2 pathway for sur-
vival (8). Results from our study help in the interpre-
tation of results obtained from functional studies
inactivating VEGF by using “VEGF-trap” (2, 5) or spe-
cific Ab’s against VEGF (6) as antiangiogenic agents. It
is likely that the treatment effects are due to the inabil-
ity of VEGF to activate VEGFR-2. As VEGFR-2 medi-
ates VEGF-dependent angiogenesis, it is less likely that
VEGFR-1 plays an important role during this process.
The role of other angiogenic factors, including
angiopoietins acting through the Tie2 receptor for
gonadotropin-dependent follicle development, must
be further defined (2, 4, 5).
A mature, preovulatory follicle is characterized by
the formation of a single, centrally located, continu-
ous, fluid-filled antrum. The antrum develops in con-
cert with the increase in vasculature surrounding the
follicle. In HX mice PMSG completes the formation
of such cavities 48 hours to 72 hours after initiation
of stimulation. The formation of follicular cavities
was completely absent in the control group, empha-
sizing its dependence on gonadotropins. Cavity for-
mation activity mediated by gonadotropins is blocked
by anti–VEGFR-2 Ab treatment, and only small, dis-
continuous fluid-filled pockets among granulosa cells
are detected. What mechanisms are used to develop
the fluid-filled antrum? VEGF is known to promote
both endothelial cell proliferation and to regulate vas-
cular permeability (18, 21); thus, one may propose
that an increase in vascular permeability might con-
tribute to the physiologic process of antrum forma-
tion (1). Our data support a role for VEGF acting
through VEGFR-2 as one factor involved in this
process (1, 22, 23); however, it is difficult to experi-
mentally segregate the mitogenic from permeability
Figure 5
(a–c) Follicular atresia 72 hours after sham or PMSG injection. (a)
C, control group follicle; (b) S, PMSG-stimulated follicle; (c) T, treat-
ment group follicle. Atretic follicles are characterized by multiple,
apoptotic granulosa cells, which appear as brown dots. Counter-
staining with methyl-green.
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functions of VEGF. It is also possible that other
gonadotropin-dependent regulators of vascular per-
meability such as angiopoietins (1, 23, 24) and regu-
lators of cell permeability such as aquaporins (25) also
participate in the process of cavity formation.
An increase in cell mass through epithelial prolifera-
tion contributes to follicular growth during follicle mat-
uration. In the stimulation group, PMSG reaching the
growing follicle through preexisting and newly formed
vessels stimulates proliferation of granulosa and theca
cells during gonadotropin-dependent maturation
beyond the level seen in the baseline and control group
follicles. In the treatment group, follicular epithelial
cells proliferate in response to gonadotropins, but at a
much lower rate when compared with the stimulation
group. Inhibition of blood vessel proliferation by angio-
genesis blocking Ab limits the amount of PMSG reach-
ing epithelial cells in the follicle, which explains why
proliferation does not reach the level seen in the stimu-
lation group. Therefore, inhibition of follicular angio-
genesis not only inhibits gonadotropin-mediated
antrum formation but also the level of proliferation of
follicular epithelial cells.
In the absence of gonadotropins, the most advanced
immature follicles belonging to class 5b are gradually
eliminated through atresia by cellular apoptosis (26).
These follicles are continuously replaced with newly
maturing follicles originating from a resting pool of
follicles (9). In ovaries of HX mice more than half of
class 5b follicles were atretic. In contrast, atretic folli-
cles were mostly absent in ovaries from HX animals
stimulated with PMSG. It thus appears that follicular
atresia in HX mice can be reversed or prevented by
gonadotropin administration (15). An angiogenic block
induced in the treatment group by anti–VEGFR-2 Ab
partially prevented the gonadotropin-dependent rever-
sal of atresia. We speculate that the failure to increase
the blood supply through angiogenesis is a contribut-
ing factor preventing PMSG-dependent reversal of atre-
sia in these ovaries. Thus, our data support that of
other groups in hypothesizing that insufficient vascu-
lar support is one of the mechanisms that contributes
to follicular atresia (5, 27).
Hormonal measures and weight parameters support
the finding that anti–VEGFR-2 Ab inhibits gonado-
tropin-dependent ovarian follicular development. Estra-
diol and progesterone levels are significantly increased
in the PMSG-stimulation group compared with control,
but no such rise was observed in the anti–VEGFR-2–
treated group. This is secondary to a failure to increase
follicular granulosa and theca cell numbers to levels seen
in preovulatory follicles of stimulation group ovaries.
Also, the amount of gonadotropins reaching treatment
group follicles is less when compared with stimulation
group follicles due to the differences in follicular vascu-
lature. Ovarian weight did not increase significantly in
anti–VEGFR-2–treated ovaries compared with gonado-
tropin-stimulated ovaries, most likely related to the
absence of advanced stage follicles in treatment ovaries.
Uterine weight was significantly lower in treatment
group animals compared with stimulation group uteri.
This failure to increase uterine weight to levels seen in
the stimulation group is likely secondary to decreased
ovarian steroid production and secretion. An additional
direct effect of angiogenic inhibitors on uterine growth,
however, cannot be excluded.
In this study we haven chosen a new model, the pre-
puberally HX mouse, to delineate the importance of
the VEGF/VEGFR-2 pathway for gonadotropin-
dependent follicular development. In contrast to pre-
vious studies (2, 5–7) where feedback is active, our a
model avoids interference by feedback when the antian-
giogenic agents are given. Using such a design elimi-
nates a confounding variable that could have an impact
on the interpretation of results.
In summary, results obtained in our HX mouse
model clearly demonstrate that high doses of exoge-
nous gonadotropins are unable to induce optimal fol-
licle development due to the intraovarian action of the
anti–VEGFR-2 Ab. Follicular angiogenesis is critical for
the development of gonadotropin-dependent, mature
antral follicles from immature ones. Further research
is needed to answer the question of whether the
VEGF/VEGFR-2 pathway is also involved in the regu-
lation of the formation of a follicular antrum through
its action on vascular permeability. In addition, it will
be important to understand what role other angiogenic
regulators, such as angiopoietins, play in follicular
angiogenesis and in follicle development.
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